Lantheus to Present at the TD Cowen 44th Annual Health Care Conference Read more about Lantheus to Present at the TD Cowen 44th Annual Health Care Conference
Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results Read more about Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results
Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging Read more about Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
Lantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February 22, 2024, at 8:00 a.m. Eastern Time Read more about Lantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February 22, 2024, at 8:00 a.m. Eastern Time
Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dotatate) Read more about Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dotatate)
Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics Read more about Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics
Lantheus Reports Preliminary Fiscal Year 2023 Revenue Read more about Lantheus Reports Preliminary Fiscal Year 2023 Revenue
Lantheus to Present at the 42nd Annual J.P. Morgan Healthcare Conference Read more about Lantheus to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer Read more about Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
